Tyrosine kinase inhibitors, widely hailed for their success as treatments for cancer, are also plagued by the issue of cardiotoxic side effects. The mechanism behind the heart damage now comes to light for one such inhibitor, imatinib mesylate, also known as Gleevec (pages 908–916).
This is a preview of subscription content, log in via an institution to check access.
Kim Caesar
References
Slamon, D.J. et al. N. Engl. J. Med. 344, 783–792 (2001).
Crone, S.A. et al. Nat. Med. 8, 459–465 (2002).
Kerkelä, R. et al. Nat. Med. 12, 908–916 (2006).
Druker, B.J. et al. N. Engl. J. Med. 344, 1031–1037 (2001).
Terai, K. et al. Mol. Cell Biol. 25, 9554–9575 (2005).
Boyce, M. & Yuan, J. Cell Death. Differ. 13, 363–373 (2006).
Kumar, S. et al. J. Biol. Chem. 276, 17281–17285 (2001).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Mann, D. Targeted cancer therapeutics: the heartbreak of success. Nat Med 12, 881–882 (2006). https://doi.org/10.1038/nm0806-881
Issue Date:
DOI: https://doi.org/10.1038/nm0806-881
- Springer Nature America, Inc.
This article is cited by
-
Managing Chemotherapy-Related Cardiotoxicity in Survivors of Childhood Cancers
Pediatric Drugs (2014)
-
The institutional review board is an impediment to human research: the result is more animal-based research
Philosophy, Ethics, and Humanities in Medicine (2011)
-
Cardiac dysfunction induced by novel targeted anticancer therapy: An emerging issue
Current Cardiology Reports (2009)
-
Cardiac toxicity: old and new issues in anti-cancer drugs
Clinical and Translational Oncology (2008)
-
In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'
Nature Medicine (2007)